APAC Cardiac Safety Services Market - Industry Trends and Forecast to 2029
- Published Date: 2022-12-24
- Report ID: 143369
- Pages: 225
-
Format:
Short Description
Asia-Pacific Cardiac Safety Services Market, By Services (ECG/Holter Measurements, Blood Pressure Measurements, In Vitro Cardiac Safety Assessment Services, Cardiovascular Imaging, Real-Time Telemetry Monitoring, Central Over-Read of ECGS, Non-Invasive Cardiac Imaging, Physiologic Stress Testing, Thorough QT Studies, TQT and Exposure Response Modeling, Platelet Aggregation and Other Services), Phase (Phase 1, Phase 2 and Phase 3), Type (Integrated Services and Standalone Services), End User (Pharmaceuticals & Biopharmaceuticals Companies, Contract Research Organizations and Academic and Research Institute) Industry Trends and Forecast to 2029
Market Definition:
Cardiac safety services generally help support and design clinical trials and other research needed to monitor heart safety. The demand for cardiac safety services market has been increased in both developed well as in developing countries and the reason behind this is the increasing number of clinical trials and product launch. The cardiac safety services market is growing due to introduction of innovative products, increasing in technological products and rising disposable income. The market will grow in forecasted period due to exploration of emerging markets, strategic initiatives by market players, increasing healthcare expenditure.
Market Segmentation:
Global cardiac safety services market is categorized into four notable segment which is services, type, phase and end user.
On the basis of services, the cardiac safety services market is segmented into ECG/Holter measurements, blood pressure measurements, in vitro cardiac safety assessment services, cardiovascular imaging, real-time telemetry monitoring, central over-read of ECGS, non-invasive cardiac imaging, physiologic stress testing, thorough QT studies, TQT and exposure response modeling, platelet aggregation and other services.
On the basis of phases, the cardiac safety services market is segmented into phase 1, phase 2 and phase 3. In 2022, phase 1 is expected to dominate the global cardiac safety services market with the increasing new drug development and rising strategic initiatives by major market players.
On the basis of type, the cardiac safety services market is segmented into integrated services and standalone services. In 2022, integrated services is expected to dominate the global cardiac safety services market with the increasing advanced technology and rising healthcare expenditure.
On the basis of end user, the cardiac safety services market is segmented pharmaceuticals & biopharmaceuticals companies, contract research organizations and academic and research institute. In 2022, hospital is expected to dominate the global cardiac safety services market with the increasing number of patients and surgeries.
Market Players
The key market players for Asia-Pacific cardiac safety services market are listed below:
Koninklijke Philips N.V.
Laboratory Corporation of America Holdings
IQVIA
Medpace
Ncardia
Certara
Eurofins Scientific
SGS SA
Banook
Celerion
TABLE OF CONTENTS
1 INTRODUCTION 17
1.1 OBJECTIVES OF THE STUDY 17
1.2 MARKET DEFINITION 17
1.3 OVERVIEW OF ASIA PACIFIC CARDIAC SAFETY SERVICES MARKET 17
1.4 LIMITATIONS 18
1.5 MARKETS COVERED 19
2 MARKET SEGMENTATION 21
2.1 MARKETS COVERED 21
2.2 GEOGRAPHICAL SCOPE 22
2.3 YEARS CONSIDERED FOR THE STUDY 23
2.4 CURRENCY AND PRICING 23
2.5 DBMR TRIPOD DATA VALIDATION MODEL 24
2.6 MULTIVARIATE MODELLING 27
2.7 SERVICES LIFELINE CURVE 27
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 28
2.9 DBMR MARKET POSITION GRID 29
2.10 MARKET END USER GRID 31
2.11 VENDOR SHARE ANALYSIS 32
2.12 SECONDARY SOURCES 33
2.13 ASSUMPTIONS 33
3 EXECUTIVE SUMMARY 34
4 PREMIUM INSIGHTS 37
4.1 PORTERS FIVE FORCES 38
4.2 PESTEL ANALYSIS 39
5 EPIDEMIOLOGY 40
5.1 INCIDENCE OF ALL BY GENDER 40
5.2 TREATMENT RATE 41
5.3 MORTALITY RATE 41
5.4 DRUG ADHERENCE AND THERAPY SWITCH MODEL 42
6 INDUSTRY INSIGHT 43
6.1 DEMOGRAPHIC TRENDS: IMPACTS ON ALL INCIDENCE RATES 43
6.2 PATENT ANALYSIS 44
6.3 PATENT FLOW DIAGRAM 45
6.4 KEY PATIENT ENROLLMENT STRATEGIES 45
6.5 PRICING STRATEGY 48
7 ASIA PACIFIC CARDIAC SAFETY SERVICES MARKET: REGULATIONS 49
8 MARKET OVERVIEW 52
8.1 DRIVERS 54
8.1.1 INCREASE IN THE NUMBER OF CLINICAL TRIALS 54
8.1.2 INCREASE IN HEALTHCARE EXPENDITURE AND FUNDING 54
8.1.3 INCREASE IN STRATEGIC INITIATIVES BY MAJOR MARKET PLAYERS 55
8.1.4 INCREASE IN R&D ACTIVITIES 55
8.2 RESTRAINTS 56
8.2.1 HIGH COST OF CARDIAC SAFETY EVALUATION 56
8.2.2 STRICT REGULATORY 56
8.3 OPPORTUNITIES: 57
8.3.1 INCREASE IN NEW DRUG DEVELOPMENT 57
8.3.2 RISE IN THE EXPANSION OF THE CARDIAC SAFETY SERVICES 58
8.4 CHALLENGES 58
8.4.1 TIME-CONSUMING PROCEDURE 58
8.4.2 LACK OF SKILLED PERSON TO OPERATE DEVICES DURING CARDIAC SAFETY EVALUATION 59
9 ASIA PACIFIC CARDIAC SAFETY SERVICES MARKET, BY SERVICES 60
9.1 OVERVIEW 61
9.2 ECG/HOLTER MEASUREMENTS 65
9.3 BLOOD PRESSURE MEASUREMENTS 65
9.4 IN VITRO CARDIAC SAFETY ASSESSMENT SERVICES 66
9.4.1 HUMAN IPSC-DERIVED CARDIOMYOCYTES MEA ASSAYS 67
9.4.1.1 1 CONCENTRATIONS 67
9.4.1.2 4 CONCENTRATIONS 67
9.4.2 COMPREHENSIVE IN VITRO PROARRHYTHMIA ASSAY (CIPA) 68
9.4.2.1 3 CONCENTRATIONS 68
9.4.2.2 5 CONCENTRATIONS 68
9.4.3 IN VITRO HERG ASSAY 68
9.4.4 OTHERS 68
9.5 CARDIOVASCULAR IMAGING 68
9.6 REAL TIME TELEMETRY MONITORING 69
9.7 CENTRAL OVER-READ OF ECGS 70
9.8 NON-INVASIVE CARDIAC IMAGING 70
9.9 PHYSIOLOGIC STRESS TESTING 71
9.10 THOROUGH QT STUDIES 72
9.11 TQT AND EXPOSURE RESPONSE MODELLING 72
9.12 PLATELET AGGREGATION 73
9.13 OTHERS 74
10 ASIA PACIFIC CARDIAC SAFETY SERVICES MARKET, BY PHASE 75
10.1 OVERVIEW 76
10.2 PHASE I 79
10.3 PHASE II 79
10.4 PHASE III 80
11 ASIA PACIFIC CARDIAC SAFETY SERVICES MARKET, BY TYPE 81
11.1 OVERVIEW 82
11.2 INTEGRATED SERVICES 85
11.3 STANDALONE SERVICES 86
12 ASIA PACIFIC CARDIAC SAFETY SERVICES MARKET, BY END USER 87
12.1 OVERVIEW 88
12.2 PHARMACEUTICALS & BIOPHARMACEUTICALS COMPANIES 91
12.3 CONTRACT RESEARCH ORGANIZATIONS 91
12.4 ACADEMIC AND RESEARCH INSTITUTE 92
13 ASIA PACIFIC CARDIAC SAFETY SERVICES MARKET, BY REGION 93
13.1 ASIA-PACIFIC 94
13.1.1 CHINA 102
13.1.2 JAPAN 105
13.1.3 SOUTH KOREA 108
13.1.4 INDIA 111
13.1.5 AUSTRALIA 114
13.1.6 SINGAPORE 117
13.1.7 THAILAND 120
13.1.8 MALAYSIA 123
13.1.9 INDONESIA 126
13.1.10 PHILIPPINES 129
13.1.11 REST OF ASIA-PACIFIC 132
14 ASIA PACIFIC CARDIAC SAFETY SERVICES MARKET: COMPANY LANDSCAPE 133
14.1 COMPANY SHARE ANALYSIS: ASIA PACIFIC 133
15 COMPANY PROFILE 134
15.1 EUROFINS SCIENTIFIC 134
15.1.1 COMPANY SNAPSHOT 134
15.1.2 REVENUE ANALYSIS 135
15.1.3 COMPANY SHARE ANALYSIS 135
15.1.4 PRODUCT PORTFOLIO 135
15.1.5 RECENT DEVELOPMENTS 136
15.1.5.1 AGREEMENTS 136
15.1.5.2 ACQUISITION 136
15.2 PPD INC. (SUBSIDIARY OF THERMO FISHER SCIENTIFIC INC) 137
15.2.1 COMPANY SNAPSHOT 137
15.2.2 REVENUE ANALYSIS 137
15.2.3 COMPANY SHARE ANALYSIS 138
15.2.4 PRODUCT PORTFOLIO 138
15.2.5 RECENT DEVELOPMENT 138
15.2.5.1 INVESTMENT 138
15.3 KONINKLIJKE PHILIPS N.V. 139
15.3.1 COMPANY SNAPSHOT 139
15.3.2 REVENUE ANALYSIS 139
15.3.3 COMPANY SHARE ANALYSIS 140
15.3.4 PRODUCT PORTFOLIO 140
15.3.5 RECENT DEVELOPMENT 140
15.3.5.1 ACQUISITION 140
15.4 IQVIA 141
15.4.1 COMPANY SNAPSHOT 141
15.4.2 REVENUE ANALYSIS 141
15.4.3 COMPANY SHARE ANALYSIS 142
15.4.4 PRODUCT PORTFOLIO 142
15.4.5 RECENT DEVELOPMENTS 142
15.4.5.1 ACQUISITION 142
15.5 LABORATORY CORPORATION OF AMERICA HOLDINGS 143
15.5.1 COMPANY SNAPSHOT 143
15.5.2 REVENUE ANALYSIS 143
15.5.3 COMPANY SHARE ANALYSIS 144
15.5.4 PRODUCT PORTFOLIO 144
15.5.5 RECENT DEVELOPMENTS 144
15.5.5.1 NEW LABORATORY 144
15.5.5.2 ACQUISITION 144
15.6 BANOOK 145
15.6.1 COMPANY SNAPSHOT 145
15.6.2 PRODUCT PORTFOLIO 145
15.6.3 RECENT DEVELOPMENT 145
15.6.3.1 AGREEMENT 145
15.7 BIOTRIAL 146
15.7.1 COMPANY SNAPSHOT 146
15.7.2 PRODUCT PORTFOLIO 146
15.7.3 RECENT DEVELOPMENT 146
15.7.3.1 NEW CENTER OPENING 146
15.8 CELERION 147
15.8.1 COMPANY SNAPSHOT 147
15.8.2 PRODUCT PORTFOLIO 147
15.8.3 RECENT DEVELOPMENT 147
15.8.3.1 NEW CENTER OPENING 147
15.9 CERTARA 148
15.9.1 COMPANY SNAPSHOT 148
15.9.2 REVENUE ANALYSIS 148
15.9.3 PRODUCT PORTFOLIO 149
15.9.4 RECENT DEVELOPMENTS 149
15.9.4.1 CONTRACT 149
15.9.4.2 ACQUISITION 149
15.10 CLARIO 150
15.10.1 COMPANY SNAPSHOT 150
15.10.2 PRODUCT PORTFOLIO 150
15.10.3 RECENT DEVELOPMENT 150
15.10.3.1 PRODUCT EXPANSION 150
15.11 MEDPACE 151
15.11.1 COMPANY SNAPSHOT 151
15.11.2 REVENUE ANALYSIS 151
15.11.3 PRODUCT PORTFOLIO 152
15.11.4 RECENT DEVELOPMENTS 152
15.11.4.1 ACQUISITION 152
15.12 NCARDIA 153
15.12.1 COMPANY SNAPSHOT 153
15.12.2 PRODUCT PORTFOLIO 153
15.12.3 RECENT DEVELOPMENT 153
15.12.3.1 PARTNERSHIP 153
15.13 NEXEL CO., LTD 154
15.13.1 COMPANY SNAPSHOT 154
15.13.2 PRODUCT PORTFOLIO 154
15.13.3 RECENT DEVELOPMENTS 154
15.13.3.1 JOINT VENTURE 154
15.13.3.2 PARTNERSHIP 155
15.14 PHYSIOSTIM 156
15.14.1 COMPANY SNAPSHOT 156
15.14.2 PRODUCT PORTFOLIO 156
15.14.3 RECENT DEVELOPMENT 156
15.14.3.1 PARTNERSHIP 156
15.15 RICHMOND PHARMACOLOGY 157
15.15.1 COMPANY SNAPSHOT 157
15.15.2 PRODUCT PORTFOLIO 157
15.15.3 RECENT DEVELOPMENT 157
15.15.3.1 EVENT 157
15.16 SGS SA 158
15.16.1 COMPANY SNAPSHOT 158
15.16.2 REVENUE ANALYSIS 158
15.16.3 PRODUCT PORTFOLIO 159
15.16.4 RECENT DEVELOPMENT 159
15.16.4.1 ACQUISITION 159
15.17 SHANGHAI MEDICILON INC. 160
15.17.1 COMPANY SNAPSHOT 160
15.17.2 PRODUCT PORTFOLIO 160
15.17.3 RECENT DEVELOPMENTS 160
15.17.3.1 PARTNERSHIP 160
15.17.3.2 PARTNERSHIP 161
16 QUESTIONNAIRE 162
17 RELATED REPORTS 164
Call Us
( India toll free )
+91 835 605 0278
( US toll free )
+1 800 601 6071
Drop us an email at
sales@prudentmarkets.com
Get your pre and post sales queries resolved by our Subject matter experts.
We will assist you to customize the report to fit your research needs.
Our prime focus is to provide qualitative and accurate data.
Feel free to order a sample report before purchase.
Your personal and confidential information is safe and secured.
